ランキング価格はじめての方へ
  1. 米国企業
  2. Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc.SONN

時価総額
$319.2万
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2013年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
9月30日		2021年
9月30日		2022年
9月30日
Net loss-5,214,119-5,725,873-12,136,526-9,076,572-6,794,771-6,854,420-17,726,384-24,265,115-24,983,961-29,721,841
Acquired in-process research and development-------7-971,477
Depreciation---------12,845
Amortization of operating lease right-of-use asset---------80,412
Share-based compensation------126,829--876,368
Prepaid expenses and other current assets165,356-120,456-221,683-113,633-22,157-116,154152,588-901,7361
Other assets---------82,959-
Accounts payable---------971,041
Accrued expenses---------727,622
Operating lease liability---------82,060-83,685
Deferred income------42,840-215,061---349,943
Net cash used in operating activities-2,704,199-1,026,940-5,367,824-509,158-724,432575,218-4,046,550---27,687,278
Purchases of in-process research and development---------896,477
Purchases of property and equipment422122472,882---
Net cash used in investing activities--2,171,424----2,442,864678,669---896,477
Proceeds from sale of preferred stock and common stock warrants, net of issuance costs---257,175348,171----2
Proceeds from sale of common stock, net of issuance costs---------2
Net cash provided by financing activities-3---23--4
Net (decrease) increase in cash-----191,713-23,094---24,569,188
Change in operating lease right-of-use asset and liability due to amended lease---------0
Issuance of common stock on vesting of restricted stock units---------2
In-process research and development in accrued expenses---------75,000
Common stock issuance costs in accrued expenses---------80,940